Inhibiting the 5-LOX pathway is seen as a promising tactic for emerging potent anti-inflammatory drugs, although currently, only one 5-LOX inhibitor (Zileuton) is available for treating allergic asthma (Wenzel and Kamada, 1996). This evidence concerns the gene ALOX5 and allergic asthma.